Loading…

The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives

Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the...

Full description

Saved in:
Bibliographic Details
Published in:Drug design, development and therapy development and therapy, 2023-01, Vol.17, p.2691-2725
Main Author: Niazi, Sarfaraz K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003
cites cdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003
container_end_page 2725
container_issue
container_start_page 2691
container_title Drug design, development and therapy
container_volume 17
creator Niazi, Sarfaraz K
description Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.
doi_str_mv 10.2147/DDDT.S424991
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d8f1afddb3ad46d2ae7f47d3cc14c10c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A770283485</galeid><doaj_id>oai_doaj_org_article_d8f1afddb3ad46d2ae7f47d3cc14c10c</doaj_id><sourcerecordid>A770283485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</originalsourceid><addsrcrecordid>eNptksFr2zAUh83YWLtut52HYDB2SFLJkiN7lxHidSukbLDsLGTpyVGxpVSyA_3vpzRZSWDoIOn5ex_2zy_L3hM8ywnj13Vdr2e_Wc6qirzILgnhfFqWJXl5cr7I3sR4j_GcznP8OrugnGOCWXmZDesNoKXvrWuRN2jRwtN2e323QtahOowtqm1UfgfhcYJq2EHntz24YYKWnXVWyQ6tIQ5JMEHSaXQn3WikGsaQSl_Q3n9TL9AvCHELarA7iG-zV0Z2Ed4d96vsz8239fLHdPXz--1ysZqqglXDVCoKjGFWAS9I0eS0KnjBWLpBRUxZ6UIypXPWmIpzqYu8aACbFERDc0IxplfZ7cGrvbwX22B7GR6Fl1Y8FXxohQyDVR0IXRoijdYNlZrNdS6BG8Y1VYowRbBKrq8H13ZsetAqJRBkdyY9f-LsRrR-J1LOFSUFTYbPR0PwD2OKTPQpWOg66cCPUeTlnM1JiTlP6McD2sr0btYZn5Rqj4tF-nV5SVlZJGr2HyotDb1V3oGxqX7W8OmkYQOyGzbRd-NgvYvn4OQAquBjDGCev5NgsZ86sZ86cZy6hH84zeYZ_jdm9C-Rdc-f</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864618077</pqid></control><display><type>article</type><title>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</title><source>Taylor &amp; Francis_OA刊</source><source>NCBI_PubMed Central(免费)</source><source>Publicly Available Content (ProQuest)</source><creator>Niazi, Sarfaraz K</creator><creatorcontrib>Niazi, Sarfaraz K</creatorcontrib><description>Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.</description><identifier>ISSN: 1177-8881</identifier><identifier>EISSN: 1177-8881</identifier><identifier>DOI: 10.2147/DDDT.S424991</identifier><identifier>PMID: 37701048</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>advanced manufacturing ; Artificial Intelligence ; drug development ; Drug Discovery ; Drugs ; fda ; Forecasts and trends ; Homeopathy ; Humans ; Machine Learning ; Materia medica and therapeutics ; Precision Medicine ; T cells ; Therapeutics ; United States ; United States Food and Drug Administration</subject><ispartof>Drug design, development and therapy, 2023-01, Vol.17, p.2691-2725</ispartof><rights>2023 Niazi.</rights><rights>COPYRIGHT 2023 Dove Medical Press Limited</rights><rights>2023 Niazi. 2023 Niazi.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</citedby><cites>FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</cites><orcidid>0000-0002-0513-0336</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493153/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493153/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37701048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niazi, Sarfaraz K</creatorcontrib><title>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</title><title>Drug design, development and therapy</title><addtitle>Drug Des Devel Ther</addtitle><description>Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.</description><subject>advanced manufacturing</subject><subject>Artificial Intelligence</subject><subject>drug development</subject><subject>Drug Discovery</subject><subject>Drugs</subject><subject>fda</subject><subject>Forecasts and trends</subject><subject>Homeopathy</subject><subject>Humans</subject><subject>Machine Learning</subject><subject>Materia medica and therapeutics</subject><subject>Precision Medicine</subject><subject>T cells</subject><subject>Therapeutics</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1177-8881</issn><issn>1177-8881</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptksFr2zAUh83YWLtut52HYDB2SFLJkiN7lxHidSukbLDsLGTpyVGxpVSyA_3vpzRZSWDoIOn5ex_2zy_L3hM8ywnj13Vdr2e_Wc6qirzILgnhfFqWJXl5cr7I3sR4j_GcznP8OrugnGOCWXmZDesNoKXvrWuRN2jRwtN2e323QtahOowtqm1UfgfhcYJq2EHntz24YYKWnXVWyQ6tIQ5JMEHSaXQn3WikGsaQSl_Q3n9TL9AvCHELarA7iG-zV0Z2Ed4d96vsz8239fLHdPXz--1ysZqqglXDVCoKjGFWAS9I0eS0KnjBWLpBRUxZ6UIypXPWmIpzqYu8aACbFERDc0IxplfZ7cGrvbwX22B7GR6Fl1Y8FXxohQyDVR0IXRoijdYNlZrNdS6BG8Y1VYowRbBKrq8H13ZsetAqJRBkdyY9f-LsRrR-J1LOFSUFTYbPR0PwD2OKTPQpWOg66cCPUeTlnM1JiTlP6McD2sr0btYZn5Rqj4tF-nV5SVlZJGr2HyotDb1V3oGxqX7W8OmkYQOyGzbRd-NgvYvn4OQAquBjDGCev5NgsZ86sZ86cZy6hH84zeYZ_jdm9C-Rdc-f</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Niazi, Sarfaraz K</creator><general>Dove Medical Press Limited</general><general>Dove</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0513-0336</orcidid></search><sort><creationdate>20230101</creationdate><title>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</title><author>Niazi, Sarfaraz K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>advanced manufacturing</topic><topic>Artificial Intelligence</topic><topic>drug development</topic><topic>Drug Discovery</topic><topic>Drugs</topic><topic>fda</topic><topic>Forecasts and trends</topic><topic>Homeopathy</topic><topic>Humans</topic><topic>Machine Learning</topic><topic>Materia medica and therapeutics</topic><topic>Precision Medicine</topic><topic>T cells</topic><topic>Therapeutics</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niazi, Sarfaraz K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Drug design, development and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niazi, Sarfaraz K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</atitle><jtitle>Drug design, development and therapy</jtitle><addtitle>Drug Des Devel Ther</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>17</volume><spage>2691</spage><epage>2725</epage><pages>2691-2725</pages><issn>1177-8881</issn><eissn>1177-8881</eissn><abstract>Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>37701048</pmid><doi>10.2147/DDDT.S424991</doi><tpages>35</tpages><orcidid>https://orcid.org/0000-0002-0513-0336</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1177-8881
ispartof Drug design, development and therapy, 2023-01, Vol.17, p.2691-2725
issn 1177-8881
1177-8881
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d8f1afddb3ad46d2ae7f47d3cc14c10c
source Taylor & Francis_OA刊; NCBI_PubMed Central(免费); Publicly Available Content (ProQuest)
subjects advanced manufacturing
Artificial Intelligence
drug development
Drug Discovery
Drugs
fda
Forecasts and trends
Homeopathy
Humans
Machine Learning
Materia medica and therapeutics
Precision Medicine
T cells
Therapeutics
United States
United States Food and Drug Administration
title The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A37%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Coming%20of%20Age%20of%20AI/ML%20in%20Drug%20Discovery,%20Development,%20Clinical%20Testing,%20and%20Manufacturing:%20The%20FDA%20Perspectives&rft.jtitle=Drug%20design,%20development%20and%20therapy&rft.au=Niazi,%20Sarfaraz%20K&rft.date=2023-01-01&rft.volume=17&rft.spage=2691&rft.epage=2725&rft.pages=2691-2725&rft.issn=1177-8881&rft.eissn=1177-8881&rft_id=info:doi/10.2147/DDDT.S424991&rft_dat=%3Cgale_doaj_%3EA770283485%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2864618077&rft_id=info:pmid/37701048&rft_galeid=A770283485&rfr_iscdi=true